BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 16818280)

  • 1. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
    Jagannath S; Richardson PG; Barlogie B; Berenson JR; Singhal S; Irwin D; Srkalovic G; Schenkein DP; Esseltine DL; Anderson KC;
    Haematologica; 2006 Jul; 91(7):929-34. PubMed ID: 16818280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
    Bao L; Lu XJ; Zhang XH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
    Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
    Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma].
    Yuan ZG; Hou J; Zhou F; Fu WJ; Chen YB; Xi H; Yang SL
    Zhonghua Xue Ye Xue Za Zhi; 2006 Oct; 27(10):653-5. PubMed ID: 17343194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
    Fukushima T; Nakamura T; Iwao H; Nakajima A; Miki M; Sato T; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Nakajima H; Motoo Y; Umehara H
    Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
    San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
    J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
    Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC
    J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
    Li J; Zhao Y; Luo SK; Huang BH; Ding Y; Tong XZ; Wang HH; Zheng D; Su C; Peng AH
    Ai Zheng; 2008 Apr; 27(4):429-34. PubMed ID: 18423132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
    Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC
    Br J Haematol; 2004 Oct; 127(2):165-72. PubMed ID: 15461622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
    Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
    Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
    Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
    Jagannath S; Durie BG; Wolf J; Camacho E; Irwin D; Lutzky J; McKinley M; Gabayan E; Mazumder A; Schenkein D; Crowley J
    Br J Haematol; 2005 Jun; 129(6):776-83. PubMed ID: 15953004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
    N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
    Kropff MH; Bisping G; Wenning D; Volpert S; Tchinda J; Berdel WE; Kienast J
    Leuk Res; 2005 May; 29(5):587-90. PubMed ID: 15755512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
    Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
    Wang YF; Deng SH; Wu T; Xu Y; Zou DH; Wang Y; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):397-400. PubMed ID: 19031743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
    Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA
    Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.